Drug Profile
Research programme: respiratory syncytial virus fusion inhibitors - Panacos Pharmaceuticals
Alternative Names: RSV fusion inhibitors - Panacos PharmaceuticalsLatest Information Update: 15 Apr 2008
Price :
$50
*
At a glance
- Originator Panacos Pharmaceuticals Inc
- Class Small molecules
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 15 Mar 2005 Panacos Pharmaceuticals has been acquired and merged into V.I. Technologies
- 30 Aug 2002 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)